G. Andre Turenne is the former CEO of Voyager Therapeutics, Inc., a biotech company focused on gene therapy. He joined the company in July 2018 after working at Sanofi, where he was the global head of business development. With a...

G. Andre Turenne is the former CEO of Voyager Therapeutics, Inc., a biotech company focused on gene therapy. He joined the company in July 2018 after working at Sanofi, where he was the global head of business development. With a Bachelor’s degree from Kalamazoo College and an MBA from the Tuck School of Business at Dartmouth, he has a solid educational foundation. During his time at Voyager, he earned around $2.6 million in total compensation for 2021, which shows a combination of salary and bonuses. He had a unique inside view of the company’s strategic aims and helped steer the business through a rapidly changing industry. Turenne had several significant insider trades, especially in early 2021. At one point, he held stock worth over $2 million, reflecting the ups and downs in stock prices. His leadership at Voyager came to a close in May 2021, marking an end to an impactful chapter in the company’s history. Turenne's experience spans various roles, particularly in business development and strategy in the biotech sector.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Voyager Therapeutics, Inc. CEOs

V

G. Andre Turenne

CEO of Voyager Therapeutics, Inc.

Education

B.A. from Kalamazoo College and M.B.A. from the Tuck School of Business at Dartmouth

Field of Expertise

Business & Management - Business Development

Sector of Economy

Healthcare

Born

January 1, 1974 - 51 years ago

CEO of Voyager Therapeutics, Inc. for

6 years 8 months (Jul 2018 - Present)

Previous Experience

Senior Vice President, Global Head, Business Development and Licensing at Sanofi

Rivals

Competitors/colleagues of G. Andre Turenne

Holdings

See how much did G. Andre Turenne make over time.

G. Andre Turenne had notable stock holdings during his tenure at Voyager Therapeutics. At one point in early 2021, his stock holdings were valued at approximately $2 million. These holdings fluctuated quite a bit, showcasing the volatility of biotech stocks....

G. Andre Turenne had notable stock holdings during his tenure at Voyager Therapeutics. At one point in early 2021, his stock holdings were valued at approximately $2 million. These holdings fluctuated quite a bit, showcasing the volatility of biotech stocks. In September 2019, he had a significant insider trade valued around $1.62 million. His holdings saw a notable peak when they reached about $4 million in mid-2023, after consistent growth in Voyager’s stock price. However, by the time of his departure in May 2021, the value was lower, reflecting the ups and downs commonly found in the biotech sector. Overall, his financial engagement with the company's stock mirrored the challenges and changes faced by Voyager.

Total Stock Sold

$292.11K

VYGR

$292.11K

29,125 VYGR shares

What if they kept their stock?

If G. Andre Turenne didn't sell their stock, today they would have:
Extra VYGR29,125 shares worth $271.15K.
This is -7.17% and $20.95K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of G. Andre Turenne.

VYGR

80,000 shares

VYGR

Mar 19, 2021

Received

VYGR

94,000 shares

VYGR

Feb 16, 2021

Received

VYGR

$60.23K

VYGR at $7.55/share

Feb 11, 2021

Sale

VYGR

$90.02K

VYGR at $8.62/share

Jan 12, 2021

Sale

VYGR

81,250 shares

VYGR

Feb 10, 2020

Received

VYGR

$143.02K

VYGR at $13.36/share

Jan 21, 2020

Sale

VYGR

96,250 shares

VYGR

Jan 11, 2019

Received

Compensation History

See how much did G. Andre Turenne make over time.

G. Andre Turenne's compensation at Voyager Therapeutics was reflective of both a strategic leadership role and the performance of the company. In 2021, he received total compensation of $738,698 which included a $600,300 base salary and a $138,398 bonus that was part of a severance agreement. His bonuses were aligned with company performance metrics, indicating a strong focus on achieving corporate goals. Over the years, his total compensation fluctuated, with amounts reaching as high as $873,480 in 2020 due to performance-based bonuses. His unique approach to compensation emphasized linking financial rewards to the company’s performance, which is a key trend in the biotech industry.

Year

2021

Total Compensation

$738.70K

Salary

$600.30K

Board Justification

The compensation programs are designed to attract and retain individuals with superior ability, align executive officers’ incentives with corporate strategies, and increase the incentive to achieve key strategic performance measures.

Bonus

$138.40K

Board Justification

Mr. Turenne’s bonus was part of his severance agreement signed on May 19, 2021 and included bi-weekly payments of $5,323 per pay period for a final bonus payout of $138,398.

Other

$0.00

Board Justification

No other compensation was reported for Mr. Turenne in 2021.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2021 for Mr. Turenne.

Performance Metrics

The corporate goals were achieved at a rate of 80% for the year ended December 31, 2021.

Other Voyager Therapeutics, Inc. CEOs

Here are other CEOs of Voyager Therapeutics, Inc.

Steven Paul, M.D.

Ex-CEO of Voyager Therapeutics, Inc.

September 2014 - July 2018